# Sermorelin Dosage in the Research Literature: Doses, Routes, and Half-Life > Sermorelin dosage as studied: 30 mcg/kg/day subcutaneous at bedtime in the pediatric trial, 0.5-1 mg twice daily in older men, 0.25-2 mcg/kg IV in PK work. Research-context framing only, cited throughout. The doses, routes, and timing used in published studies — described as study protocols, never as a recommendation for human use. ## The short version This page reports sermorelin dosage the way the studies recorded it — what was given, to whom, by what route — not a recipe for taking it. In the children's growth trial, sermorelin was injected under the skin once a day at bedtime. In studies of older men, it was injected twice a day for two weeks. In lab pharmacology studies, small doses were given into a vein to measure the growth-hormone response. The peptide clears fast, in about ten minutes. Everything below describes research protocols, with each figure tied to its study. ## Doses used in the research literature Sermorelin dosage in the published record spans pediatric treatment, aging research, and pharmacology. In the pediatric GH-deficiency efficacy work, GHRH(1-29) was given at 30 mcg/kg/day subcutaneously at bedtime [1][8]. In aging research in older men, the doses were 0.5 mg and 1 mg subcutaneously twice daily for 14 days [2]. In short children with normal GH, 5 mcg/kg subcutaneously each evening for 6 months was studied [10]. For pharmacokinetics and GH-release characterization, intravenous doses of 0.25-2 mcg/kg were used in healthy men [3], and diagnostic GHRH stimulation historically used a single intravenous bolus of about 1 mcg/kg [11]. These are study protocols; none is a human dosing recommendation, and growth hormone secretagogues are prohibited in sport (see below). ## Subcutaneous injection in the studies Subcutaneous injection was the primary route across the efficacy literature. The pediatric registration trial dosed once daily subcutaneously at bedtime [1]; the older-men study dosed subcutaneously twice daily for 14 days [2]; the short-children study dosed subcutaneously each evening [10]. Bedtime timing was deliberate — it aligns the GHRH signal with the body's largest natural GH pulse during early slow-wave sleep. Intravenous dosing was reserved for pharmacokinetic and diagnostic work [3][11]. ## Routes studied and why bioavailability matters Three routes appear in the record, with very different efficiency. Subcutaneous injection was the workhorse. Intravenous administration was used in PK and diagnostic studies [3]. Intranasal delivery was tried historically but reached only ~3-5% bioavailability [3], and a 6-month pediatric intranasal pilot at 50 mcg/kg three times daily failed to increase height velocity and provoked antibody formation [7]. That low mucosal absorption is also why oral, sublingual, and troche "sermorelin" formulations are widely criticized in research-user communities as ineffective — peptides are degraded in the gut and poorly absorbed across mucosa. ## Half-life and stability Sermorelin's plasma half-life is short — on the order of ~10-12 minutes after intravenous administration — yet a single dose keeps serum GH elevated for roughly 3 hours [3]. That brevity drove the development of longer-acting analogs (the D-Ala2 substitution and the DAC technology behind CJC-1295). On stability: lyophilized sermorelin acetate is reconstituted with sterile diluent and then typically refrigerated, because aqueous peptide solutions degrade — the reason it is supplied as a dry powder. Compounded preparations are prepared under USP <797> sterile-compounding standards. ## Dose and the growth-hormone response Where the dose-response relationship was actually measured, it was in pharmacology, not in self-dosing. In healthy men, intravenous GHRH(1-29)NH2 elicited significant GH release at doses as low as 0.25 mcg/kg, with maximal release at roughly 1-2 mcg/kg [3] — beyond which more peptide did not buy proportionally more GH. The pediatric efficacy doses (30 mcg/kg/day subcutaneously) and the older-men aging doses (0.5-1 mg subcutaneously twice daily) were the regimens that produced measured endpoints — accelerated height velocity [1] and restored 24-hour GH/IGF-1 [2] — over weeks to a year. The lesson from the record is that the GH response saturates, and that timing and route mattered as much as the number on the syringe. None of this is a prescription; it is a description of what investigators measured. ## How long studies ran Study durations were set by the endpoint, not by a fixed "course." Pharmacokinetic GH-release work measured a single dose over hours [3]. The older-men GH/IGF-1 reversal was assessed over 14 days [2]. The older-adult cognition trial ran 20 weeks [6]. Pediatric height-velocity outcomes were measured over a full year, and a long-term pediatric study continued GHRH(1-29) at 30 mcg/kg/day for up to 24 months in responders [1][8]. There is no established standard length for adult use because there is no established adult indication — the durations in the literature track what each study was trying to measure. ## A note on framing Everything on this page is research context. The doses above are what investigators administered to defined study populations by defined routes — not instructions for self-administration. Growth hormone secretagogues, including GHRH analogs, are prohibited in sport by WADA under the hormone-and-metabolic-modulators category (S2), and dedicated LC-MS/MS detection methods exist [13]. Long-term adult tolerability data are limited, and authorities have cautioned that secretagogue use for aging is not established [5]. Where you see a specific milligram or microgram figure on this page, read it as "studied at X in [population], by [route]" — the framing the research supports — and nothing more. --- A status-console reading of the sermorelin record — every regulatory and GH/IGF-1 fact tagged with its source and its operational state, the formerly-approved-now-compounded standing reported as filed and the thin adult anti-aging evidence flagged in plain view; no clinic behind this console and nothing here dosed, dispensed, or sold.